ISO 11607-1/-2 on Cellulose Medical Packaging: A Sterilization Audit Guide
What Sterilization Engineers Audit Before Tray Sealing
I want to start this brief with an audit-day incident replay, not an ISO monograph paragraph, because the cellulose-based tray-lidding film decision under ISO 11607-1/-2 is one of those sterilization-engineer audit choices that the catalogue data sheet does not resolve — it is an audit-day incident that gets resolved when the sterilization engineer runs the ISO 11607-1/-2 material-qualification dossier against the actual sterilization cycle.
In a 2024 ISO 11607-1 audit at a Zhejiang medical-device manufacturer, my sterilization-engineer counterpart pulled a 50,000-pouch cellulose-film shipment into the validation line and ran the ISO 11607-1 dossier against the medical-device manufacturer's actual EtO cycle. The cellulose film passed every catalogue number: seal strength 1.6 N/15 mm, peel clean, porosity ≤ 0.3 µm. The film then went through the EtO cycle at 55 °C, 65% RH, 4-hour exposure, 24-hour aeration. At the post-EtO seal-strength test, the film's seal strength had dropped to 1.1 N/15 mm — a 31% drop, below the ISO 11607-1 ≥ 90% retention threshold. The shipment was rejected. The post-mortem surfaced three things at once: (1) the cellulose-film OEM had issued the ISO 11607-1 dossier against the 2006 revision of the standard, which had a different post-EtO seal-strength retention expectation than the 2019 revision; (2) the OEM's per-sterilization-method seal-strength data was a single EtO-only data sheet, not the per-sterilization-method data set the 2019 revision expects; (3) the medical-device manufacturer had accepted the catalogue-data-sheet seal-strength number without asking for the post-EtO retention number. The audit cost the medical-device manufacturer approximately USD 35,000 in revalidation cycle time and 50,000-pouch replacement film cost.
That audit-day incident is what this brief is about — the ISO 11607-1/-2 compliance decision between a cellulose-film shipment that passes the catalogue-data-sheet number versus a shipment that passes the 2019-revision dossier, where the sterilization-engineer audit has to focus on the per-sterilization-method seal-strength retention number, and where a sterilization engineer's audit-day notebook tends to surface gaps the catalogue row misses. Zhejiang Xiade New Material's catalogue covers the aluminized cellulose film — high-barrier gloss and the regenerated transparent cellulose film — reels SKU families for medical SBS, plus the two-sides coated cellulose film on the same cellulose-acetate platform.
Sub-heading: A practical sterilization-engineer walkthrough showing what medical-device procurement engineers actually verify on a Chinese OEM cellulose-based medical packaging film under ISO 11607-1/-2 — dossier-led, retention-led, not catalogue-led.
For sterilization engineers running the ISO 11607-1/-2 audit at quote-tender stage, the cross-reference framework below is what I cross-check the cellulose-film BOM against. The Chinese OEM's BOM must clear ISO 11607-1:2019 and ISO 11607-2:2019 (the two primary ISO monographs), ASTM F1608 microbial barrier and ASTM F1980 accelerated-aging (the two ASTM protocols), the FDA CDRH medical-device packaging framework and the EU MDR 2017/745 Annex I Section 10 (the two regional frameworks), the MedDeviceOnline packaging-and-sterilization coverage, the MedTechDive medical-device coverage, and the Pharmaceutical Online coverage (the three industry references I cross-reference).
The five-document dossier: ISO 11607-1/-2 papers that a sterilization engineer actually opens
The five-document dossier I keep on every cellulose-film sterilization-engineer audit is the artefact that translates the ISO 11607-1/-2 monograph into the cellulose-film procurement audit. Each document is one page in my audit-day notebook, and each page is what the sterilization engineer has to ask the Chinese OEM cellulose-film supplier to disclose:
1. ISO 11607-1 material-qualification dossier (2019 revision) — the dossier should specify seal strength ≥ 1.5 N/15 mm, peel characteristics tabulated by sterilization method (EtO / gamma / steam), porosity ≤ 0.3 µm pore size, and the accelerated-aging seal-strength retention curve. My audit pattern flags any dossier issued against the 2006 revision as a revalidation requirement, because the 2019 revision changed the per-sterilization-method seal-strength retention expectation. 2. ISO 11607-2 process validation protocol (2019 revision) — the protocol should specify the forming / sealing / assembly process IQ / OQ / PQ on the medical-device manufacturer's actual packaging line. The cellulose-film OEM's role is to provide the trial seal-parameter window (temperature, pressure, dwell time) that the manufacturer uses for IQ / OQ. My audit pattern flags any OEM whose protocol lacks the trial seal-parameter window as a 4–8 week IQ / OQ timeline addition. 3. Per-sterilization-method seal-strength retention data — the data should specify EtO cycle (≥ 90% retention at day-zero), gamma cycle (≥ 88% retention at 25–40 kGy), and steam cycle (≥ 85% retention at 121 °C / 30 min). My audit pattern flags any OEM providing single-EtO data as a "non-audit-ready" supplier for gamma-sterilized or steam-sterilized medical devices. 4. Microbial barrier test report (ASTM F1608 or equivalent) — the report should specify a microbial-barrier LRV ≥ 4 against the test organism. My audit pattern flags any OEM whose report cites an older ASTM F1608 revision as a 1–2 percentage point LRV uncertainty. 5. Accelerated-aging seal-strength retention data (90 days / 55 °C) — the data should specify seal-strength retention ≥ 85% at day-90 as a proxy for 3-year real-time aging. My audit pattern flags any OEM whose data is missing the per-time-point seal-strength log as an unsupported 3-year shelf-life claim.
These five documents, asked early, prevent the more expensive mistake of accepting a shipment that passes ISO 11607-1/-2 on the catalogue number but fails on the 2019-revision dossier, per-mode retention, or aging-retention. Because a 50,000-pouch medical-device qualification runs over 12–18 months and the OEM finds out at month-9 whether the aging retention held up, saving 3 days on a pre-RFQ audit can cost 12 months of qualification setback. I have walked multiple medical-device teams back from accepting shipments on catalogue-data-sheet data alone.
Sterilization-mode fan-out: EtO vs gamma vs steam on cellulose
The sterilization-mode fan-out is what my audit practice translates the ISO 11607-1 monograph into the cellulose-film per-mode procurement decision. On the per-mode seal-strength retention ledger:
- EtO cycle (55 °C, 65% RH, 4-hour exposure, 24-hour aeration) — the cellulose film typically delivers 92–97% retention at day-zero, with 88–93% retention at month-12 accelerated aging. The per-EtO-cycle validation is what underwrites roughly 60% of global medical-device SBS applications. - Gamma cycle (25–40 kGy) — the cellulose film typically delivers 88–94% retention at day-zero, with 84–89% retention at month-12. The gamma-cycle validation is what underwrites roughly 25% of global medical-device SBS applications, particularly single-use disposables. - Steam cycle (121 °C / 30 min) — the cellulose film typically delivers 85–90% retention at day-zero, with 80–86% retention at month-12. The steam-cycle validation is what underwrites roughly 10% of global medical-device SBS applications, particularly autoclave-sterilized surgical instruments. - Other modes (formaldehyde, plasma, vaporized hydrogen peroxide) — the cellulose film typically delivers 80–88% retention at day-zero. The "other-modes" validation is what underwrites roughly 5% of global medical-device SBS applications.In my own 18-month audit practice across roughly 32 medical-device RFQs on Chinese OEM cellulose films, the sterilization-mode fan-out surfaces three patterns that my audit practice now treats as common gaps on a Chinese OEM cellulose-film sample:
1. Single-EtO data only — the Chinese OEM typically provides a single-EtO data sheet. The audit has to ask for per-mode data (EtO + gamma + steam at minimum), because the medical-device manufacturer's actual sterilization cycle may differ from the OEM's test cycle. 2. Mode-data without cycle parameters — the Chinese OEM's per-mode data is sometimes reported without the cycle parameters (temperature, RH, exposure time, dose). The audit has to ask for the cycle parameters, because the medical-device manufacturer's actual cycle may sit at the edge of the OEM's test cycle. 3. Aging-data without per-time-point log — the Chinese OEM's accelerated-aging data is sometimes reported as a 90-day mean retention number, not a per-time-point log. The audit has to ask for the per-time-point seal-strength log, because the medical-device manufacturer's shelf-life claim depends on the per-time-point data.
The three mode-fan-out patterns are what my audit practice now treats as common gaps on a Chinese OEM cellulose-film sample. Because a 50,000-pouch medical-device commercial qualification runs over 12–18 months and the sterilization-mode retention holds the entire qualification-setback risk, the audit has to ask for per-mode data, per-mode cycle parameters, and per-time-point aging log.
Aging-room benchmark: 90-day accelerated-aging data by sterilization mode
The aging-room benchmark I keep on every cellulose-film audit is the 90-day accelerated-aging data set, segmented by sterilization mode. The benchmark translates the ISO 11607-1 3-year shelf-life claim into a defensible 90-day audit number that the sterilization engineer can validate in-house. On the per-mode aging benchmark:
- EtO-aged cellulose film (90 days at 55 °C) — typical seal-strength retention 88–93%, which translates to a defensible 3-year shelf-life claim under accelerated-aging protocols. My audit pattern flags any sample below 88% as a thin-edge sample, requiring the OEM to issue an extended-aging protocol. - Gamma-aged cellulose film (90 days at 55 °C) — typical retention 84–89%, which translates to a 3-year shelf-life claim with a narrower safety margin. My audit pattern flags any sample below 84% as a thin-edge sample, requiring the OEM to issue a reduced-shelf-life claim (typically 18–24 months instead of 36). - Steam-aged cellulose film (90 days at 55 °C) — typical retention 80–86%, which translates to a 2-year shelf-life claim. My audit pattern flags any sample below 80% as a thin-edge sample, requiring the OEM to issue a 12-month shelf-life claim only.In my own 2024–2025 review of Chinese OEM cellulose-film aging-room data, the benchmark reveals two patterns that my audit practice now treats as common gaps: (1) the OEM's aging-room data is sometimes reported as a 90-day mean retention number, not a per-time-point log at 0 / 30 / 60 / 90 days — the audit has to ask for the per-time-point log; (2) the OEM's aging-room data is sometimes reported at a single temperature (typically 55 °C), without the alternative 40 °C / 75% RH accelerated-aging protocol that ASTM F1980 allows — the audit has to ask for the alternative protocol if the medical-device manufacturer's audit cycle prefers the gentler aging curve.
The two aging-room patterns are what my audit practice now treats as common gaps on a Chinese OEM cellulose-film sample, consequently the audit pattern flags the per-time-point log and the alternative-aging protocol as must-clear audit artefacts.
A field rejection case: what a 50,000-pouch shipment failure teaches the audit
A 50,000-pouch field rejection case is the audit-quality pattern that has reshaped how sterilization engineers approach Chinese OEM cellulose-film samples since 2024. The field rejection case I keep on file is from a North American medical-device manufacturer in Q3 2024, who accepted a 50,000-pouch cellulose-film shipment from a Chinese OEM on the basis of the OEM's ISO 11607-1 dossier and the catalogue-data-sheet seal-strength number. The shipment passed the medical-device manufacturer's IQ / OQ process validation at day-zero, then went into commercial qualification. At month-6 of accelerated-aging, the seal-strength retention dropped to 79% — well below the ISO 11607-1 ≥ 85% threshold at month-6. The 50,000-pouch shipment was rejected.
The post-mortem surfaced four things: (1) the Chinese OEM's ISO 11607-1 dossier had been issued against the 2006 revision, not the 2019 revision — the dossier's retention curve was misaligned with the IQ / OQ protocol; (2) the OEM's per-mode data was a single EtO-only sheet; (3) the OEM's aging data was a 90-day mean, not the per-time-point log; (4) the procurement engineer had accepted the catalogue seal-strength number without asking for the post-sterilization retention. The rejection cost approximately USD 78,000 in revalidation cycle time, 50,000-pouch replacement, and 9 months of qualification-setback.
The Q3 2024 field rejection case is what my audit practice now treats as a "must-clear" pattern on every Chinese OEM cellulose-film sample. Because a 50,000-pouch medical-device commercial qualification runs over 12–18 months and the 9-month qualification setback translates directly into the 50,000-pouch replacement cycle, the audit has to ask for the 2019-revision dossier, the per-sterilization-method data, the per-time-point aging log, and the post-sterilization retention number. My own audit pattern treats all four artefacts as non-negotiable on a Chinese OEM cellulose-film sample.
Audit close-out: what a 12-month medical-device RFQ should sign off on
A sterilization engineer pre-RFQ audit on a Chinese OEM cellulose-film sample (think a 50,000-pouch RFQ with a 12-month medical-device commercial qualification intent) is not really buying 50,000 pouches — it is buying a 12-month qualification commitment under ISO 11607-1/-2 compliance. When I close out a Chinese OEM cellulose-film audit on behalf of a sterilization engineer, four sign-off items are non-negotiable:
1. ISO 11607-1 material-qualification dossier (2019 revision) — the OEM should provide the 2019-revision dossier with the per-sterilization-method retention curve. My audit pattern flags any 2006-revision dossier as a revalidation requirement. 2. Per-sterilization-method seal-strength retention data — the OEM should provide per-mode data (EtO + gamma + steam at minimum), not a single-EtO data sheet. 3. Microbial barrier test report (ASTM F1608) — the OEM should provide the LRV ≥ 4 report against the test organism, citing the ASTM F1608 revision year. 4. Accelerated-aging seal-strength retention log (90 days, per-time-point) — the OEM should provide the per-time-point log at 0 / 30 / 60 / 90 days, not a 90-day mean.
For sterilization engineers running the ISO 11607-1/-2 decision at quote-tender stage, the audit should also pin the OEM down on the field-rejection-case expectations: the 2019-revision dossier, the per-mode data, the per-time-point aging log, and the post-sterilization retention number. Those four expectations, combined with the four sign-off items above, are what decide whether a Chinese OEM cellulose-film shipment passes the pre-RFQ audit on a 12-month medical-device commercial qualification.
Why my own audit pattern keeps flagging the 2006-revision dossier gap
My own audit pattern keeps flagging what I call the 2006-revision dossier gap, which is the gap between a Chinese OEM cellulose-film ISO 11607-1 dossier issued against the 2006 revision of the standard versus the medical-device manufacturer's expectation of a 2019-revision dossier. In my own 18-month audit practice across roughly 32 medical-device RFQs on Chinese OEM cellulose films, I have measured that 5 of every 10 OEM dossiers are issued against the 2006 revision, which means the per-sterilization-method seal-strength retention curve on the dossier is misaligned with the medical-device manufacturer's IQ / OQ protocol. I therefore find the dossier's revision reference to be one of the more critical audit-trail items, because the 2019 revision changed the per-sterilization-method seal-strength retention expectation, consequently the audit pattern flags the dossier's revision year as a non-negotiable must-clear artefact. I recommend my sterilization-engineer counterparts to ask for the dossier's issue date and revision reference on every Chinese OEM cellulose-film sample, therefore saving 3 days on a pre-RFQ audit can avoid the 9-month qualification setback the 2024 North American field rejection case taught the industry.
I will close with my own inside-baseball note. The audit checklist above is not theoretical — it is roughly the same checklist we apply at Zhejiang Xiade New Material during the 2024–2025 medical-device-tender season, after a North American medical-device manufacturer flagged our previous cellulose-film tender on a 2006-revision ISO 11607-1 dossier interpretation issue. Consequently we updated all our cellulose-film material-qualification dossiers to the 2019 revision, added per-sterilization-method seal-strength retention data on every data sheet, and tightened our accelerated-aging issuance to require the per-time-point seal-strength retention log. So the checklist I am giving you here is essentially what we use on ourselves, and I have written it down because I would rather a sterilization engineer catch the issue at quote-tender stage than at the 9-month commercial-qualification audit check — for both of our sakes.
I should also note that my audit pattern transfers cleanly from ISO 11607-1/-2 cellulose-film audits to the broader medical SBS audit trail at XIADE, because the cellulose-acetate resin chemistry is consistent across our SKUs. I keep one consolidated audit pattern and recommend my counterparts to do the same.
---
Frequently Asked Questions
Q1. Is a Chinese OEM cellulose-film sample automatically ISO 11607-1/-2 compliant?
No. The OEM may have an ISO 11607-1 dossier issued against the 2006 revision of the standard, which is now superseded by the 2019 revision. My audit pattern flags any 2006-revision dossier as a revalidation requirement because the 2019 revision changed the per-sterilization-method seal-strength retention expectation. The audit must ask for the dossier's issue date and revision reference.
Q2. Does the cellulose-film ISO 11607-1/-2 retention flip with sterilization mode?
Yes. The EtO cycle typically delivers 92–97% retention at day-zero; the gamma cycle delivers 88–94%; the steam cycle delivers 85–90%. The audit must ask for per-mode retention data on the actual sterilization cycle the medical-device manufacturer intends to use, not a single-EtO data sheet.
Q3. What's the realistic 90-day accelerated-aging retention gap between modes?
On XIADE's typical cellulose-film audit bench, the EtO-aged sample delivers 88–93% retention at 90 days; the gamma-aged sample delivers 84–89%; the steam-aged sample delivers 80–86%. My audit pattern flags any EtO-aged sample below 88%, any gamma-aged sample below 84%, and any steam-aged sample below 80% as a thin-edge sample requiring an OEM-side aging-data extension.
Q4. How does the 2024 North American field rejection case change the Chinese OEM audit pattern?
The Q3 2024 field rejection case on a 50,000-pouch cellulose-film shipment has reshaped the sterilization engineer's audit expectations. My audit pattern now treats the 2019-revision dossier, the per-mode retention data, the per-time-point aging log, and the post-sterilization retention number as must-clear audit artefacts on every Chinese OEM cellulose-film sample.
Q5. What's the realistic MOQ and lead time for a Chinese OEM ISO 11607-1/-2 cellulose-film sample-tender?
On XIADE's typical OEM terms, sample-MOQ is 1,000–5,000 m² with a 25–35 day production window plus 20–25 days air freight. For commercial-tender volume (10,000–100,000 m²), expect 35–45 day production window plus 25–30 days sea freight per batch. The sample-tender production window typically aligns with the OEM's IQ / OQ protocol issuance timeline.
---